Background: Injecting drug use is an important risk factor for transmission of viral hepatitis, but detailed, transparent estimates of the scale of the issue do not exist. We estimated national, regional, and global prevalence and population size for hepatitis C virus (HCV) and hepatitis B virus (HBV) in injecting drug users (IDUs). Methods: We systematically searched for data for HBV and HCV in IDUs in peer-reviewed databases (Medline, Embase, and PsycINFO), grey literature, conference abstracts, and online resources, and made a widely distributed call for additional data. From 4386 peer-reviewed and 1019 grey literature sources, we reviewed 1125 sources in full. We extracted studies into a customised database and graded them according ...
Background: WHO aims to eliminate the hepatitis C virus (HCV) as a public health threat by 2030. Inj...
Background and AimsPeople who have recently injected drugs are a priority population in efforts to a...
Knowledge of hepatitis B and C prevalence, and numbers infected, are important for planning response...
BACKGROUND AND AIMS: People who have recently injected drugs are a priority population in efforts to...
BACKGROUND AND AIMS: People who have recently injected drugs are a priority population in efforts to...
Background and Aims: People who have recently injected drugs are a priority population in efforts to...
BACKGROUND: Sharing of equipment used for injecting drug use (IDU) is a substantial cause of disease...
Summary: Background: Sharing of equipment used for injecting drug use (IDU) is a substantial cause ...
OBJECTIVE: In this paper, we review evidence of HCV prevalence among injecting drug users (IDUs) wor...
Background: Sharing of equipment used for injecting drug use (IDU) is a substantial cause of disease...
Background: People who inject drugs (PWID) are a key population affected by hepatitis C virus (HCV)....
People who inject drugs (PWID) are a key population affected by hepatitis C virus (HCV). Treatment o...
People who inject drugs (PWID) are a key population affected by hepatitis C virus (HCV). Treatment o...
AIM: This systematic review and meta-analysis characterizes the prevalence of hepatitis C virus (HCV...
BACKGROUND:People who inject drugs (PWID) are a key population affected by hepatitis C virus (HCV). ...
Background: WHO aims to eliminate the hepatitis C virus (HCV) as a public health threat by 2030. Inj...
Background and AimsPeople who have recently injected drugs are a priority population in efforts to a...
Knowledge of hepatitis B and C prevalence, and numbers infected, are important for planning response...
BACKGROUND AND AIMS: People who have recently injected drugs are a priority population in efforts to...
BACKGROUND AND AIMS: People who have recently injected drugs are a priority population in efforts to...
Background and Aims: People who have recently injected drugs are a priority population in efforts to...
BACKGROUND: Sharing of equipment used for injecting drug use (IDU) is a substantial cause of disease...
Summary: Background: Sharing of equipment used for injecting drug use (IDU) is a substantial cause ...
OBJECTIVE: In this paper, we review evidence of HCV prevalence among injecting drug users (IDUs) wor...
Background: Sharing of equipment used for injecting drug use (IDU) is a substantial cause of disease...
Background: People who inject drugs (PWID) are a key population affected by hepatitis C virus (HCV)....
People who inject drugs (PWID) are a key population affected by hepatitis C virus (HCV). Treatment o...
People who inject drugs (PWID) are a key population affected by hepatitis C virus (HCV). Treatment o...
AIM: This systematic review and meta-analysis characterizes the prevalence of hepatitis C virus (HCV...
BACKGROUND:People who inject drugs (PWID) are a key population affected by hepatitis C virus (HCV). ...
Background: WHO aims to eliminate the hepatitis C virus (HCV) as a public health threat by 2030. Inj...
Background and AimsPeople who have recently injected drugs are a priority population in efforts to a...
Knowledge of hepatitis B and C prevalence, and numbers infected, are important for planning response...